Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JCXH-105 by Immorna Hangzhou Biotechnology for Herpes Zoster (Shingles): Likelihood of Approval
JCXH-105 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Herpes Zoster (Shingles). According to...
JCXH-221 by Immorna Hangzhou Biotechnology for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
JCXH-221 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According...
JCXH-108 by Immorna Hangzhou Biotechnology for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
JCXH-108 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections....
JCXH-211 by Immorna Hangzhou Biotechnology for Solid Tumor: Likelihood of Approval
JCXH-211 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData,...